was read the article
array:24 [ "pii" => "S2173574314000379" "issn" => "21735743" "doi" => "10.1016/j.reumae.2013.07.004" "estado" => "S300" "fechaPublicacion" => "2014-03-01" "aid" => "602" "copyright" => "Elsevier España, S.L.. All rights reserved" "copyrightAnyo" => "2013" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2014;10:101-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1604 "formatos" => array:3 [ "EPUB" => 55 "HTML" => 1087 "PDF" => 462 ] ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S1699258X13001976" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2013.07.009" "estado" => "S300" "fechaPublicacion" => "2014-03-01" "aid" => "602" "copyright" => "Elsevier España, S.L." "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2014;10:101-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4270 "formatos" => array:3 [ "EPUB" => 153 "HTML" => 3265 "PDF" => 852 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Brief Report</span>" "titulo" => "Minimum Effective Dosages of Anti-TNF in Rheumatoid Arthritis: A Cross-sectional Study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "101" "paginaFinal" => "104" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Dosis efectiva mínimas de anti-TNF en artritis reumatoide: un estudio transversal" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1172 "Ancho" => 2000 "Tamanyo" => 128109 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Percentage of responders (DAS28 ≤3.2) and non-responders (DAS28 >3.2) in the different dosage regimens of anti-TNF treatments. ETN: etanercept; ADA; adalimumab; IFX: infliximab. Reduced (the time between doses was longer or the doses were lower than the standard ones). Standard (according to the approved prescribing information): ETN 25<span class="elsevierStyleHsp" style=""></span>mg twice a week or 50<span class="elsevierStyleHsp" style=""></span>mg weekly, ADA 40<span class="elsevierStyleHsp" style=""></span>mg every other week, and IFX 3<span class="elsevierStyleHsp" style=""></span>mg/kg every 8 weeks. Escalated (the time between doses was shorter or the doses were higher than the standard ones).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Inmaculada de la Torre, Lara Valor, Juan Carlos Nieto, María Montoro, Luis Carreño" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Inmaculada" "apellidos" => "de la Torre" ] 1 => array:2 [ "nombre" => "Lara" "apellidos" => "Valor" ] 2 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Nieto" ] 3 => array:2 [ "nombre" => "María" "apellidos" => "Montoro" ] 4 => array:2 [ "nombre" => "Luis" "apellidos" => "Carreño" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574314000379" "doi" => "10.1016/j.reumae.2013.07.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574314000379?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X13001976?idApp=UINPBA00004M" "url" => "/1699258X/0000001000000002/v2_201404030117/S1699258X13001976/v2_201404030117/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574313001378" "issn" => "21735743" "doi" => "10.1016/j.reumae.2013.12.006" "estado" => "S300" "fechaPublicacion" => "2014-03-01" "aid" => "596" "copyright" => "Elsevier España, S.L." "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2014;10:105-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2560 "formatos" => array:3 [ "EPUB" => 56 "HTML" => 2106 "PDF" => 398 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Brief Report</span>" "titulo" => "Comparative Study of Both Versions of an Immunoassay Commercialized for Therapeutic Drug Monitoring of Adalimumab in Rheumatoid Arthritis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "105" "paginaFinal" => "108" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Estudio comparativo de las 2 versiones de un inmunoanálisis comercializado para la monitorización terapéutica de adalimumab en artritis reumatoide" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1551 "Ancho" => 1564 "Tamanyo" => 132359 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Comparison study by correlation analysis of adalimumab concentrations determined with the 2 versions of marketed kits (n=140). A correlation coefficient of 0.896 (Version 2<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.907, Version 1 2536+) and a concordance correlation coefficient of 0.85 (95% CI: 0.80–0.89) has been obtained. gr1 Version Version Y: Concentration of adalimumab determined with V2 X: Concentration of adalimumab determined with V1.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Francisca Llinares-Tello, José Rosas, Inmaculada de la Torre, Lara Valor, Xavier Barber, José Miguel Senabre" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Francisca" "apellidos" => "Llinares-Tello" ] 1 => array:2 [ "nombre" => "José" "apellidos" => "Rosas" ] 2 => array:2 [ "nombre" => "Inmaculada" "apellidos" => "de la Torre" ] 3 => array:2 [ "nombre" => "Lara" "apellidos" => "Valor" ] 4 => array:2 [ "nombre" => "Xavier" "apellidos" => "Barber" ] 5 => array:2 [ "nombre" => "José Miguel" "apellidos" => "Senabre" ] 6 => array:1 [ "colaborador" => "the AIR-MB-HUGM Group" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X13001794" "doi" => "10.1016/j.reuma.2013.07.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X13001794?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574313001378?idApp=UINPBA00004M" "url" => "/21735743/0000001000000002/v2_201403290120/S2173574313001378/v2_201403290120/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173574313001494" "issn" => "21735743" "doi" => "10.1016/j.reumae.2013.12.018" "estado" => "S300" "fechaPublicacion" => "2014-03-01" "aid" => "581" "copyright" => "Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2014;10:94-100" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2882 "formatos" => array:3 [ "EPUB" => 55 "HTML" => 2256 "PDF" => 571 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Tocilizumab in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-modifying Antirheumatic Drugs or Tumor Necrosis Factor Inhibitors: Subanalysis of Spanish Results of an Open-label Study Close to Clinical Practice" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "94" "paginaFinal" => "100" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: subanálisis de los datos españoles de un estudio abierto cercano a la práctica clínica habitual" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 969 "Ancho" => 2100 "Tamanyo" => 96078 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Percentage of patients in clinical remission (DAS28<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>2.6) or low disease activity (DAS28<span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>3.2) at 6 months of starting treatment with tocilizumab.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José M. Álvaro-Gracia, Antonio Fernández-Nebro, Alicia García-López, Manuel Guzmán, Francisco J. Blanco, Francisco J. Navarro, Sagrario Bustabad, Yolanda Armendáriz, José A. Román-Ivorra" "autores" => array:10 [ 0 => array:2 [ "nombre" => "José M." "apellidos" => "Álvaro-Gracia" ] 1 => array:2 [ "nombre" => "Antonio" "apellidos" => "Fernández-Nebro" ] 2 => array:2 [ "nombre" => "Alicia" "apellidos" => "García-López" ] 3 => array:2 [ "nombre" => "Manuel" "apellidos" => "Guzmán" ] 4 => array:2 [ "nombre" => "Francisco J." "apellidos" => "Blanco" ] 5 => array:2 [ "nombre" => "Francisco J." "apellidos" => "Navarro" ] 6 => array:2 [ "nombre" => "Sagrario" "apellidos" => "Bustabad" ] 7 => array:2 [ "nombre" => "Yolanda" "apellidos" => "Armendáriz" ] 8 => array:2 [ "nombre" => "José A." "apellidos" => "Román-Ivorra" ] 9 => array:1 [ "colaborador" => "ACT SURE" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X13001496" "doi" => "10.1016/j.reuma.2013.07.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X13001496?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574313001494?idApp=UINPBA00004M" "url" => "/21735743/0000001000000002/v2_201403290120/S2173574313001494/v2_201403290120/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Brief Report</span>" "titulo" => "Minimum Effective Dosages of Anti-TNF in Rheumatoid Arthritis: A Cross-sectional Study" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "101" "paginaFinal" => "104" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Inmaculada De La Torre, Lara Valor, Juan Carlos Nieto, María Montoro, Luis Carreño" "autores" => array:5 [ 0 => array:4 [ "nombre" => "Inmaculada" "apellidos" => "De La Torre" "email" => array:1 [ 0 => "Inma.torre.ortega@googlemail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Lara" "apellidos" => "Valor" ] 2 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Nieto" ] 3 => array:2 [ "nombre" => "María" "apellidos" => "Montoro" ] 4 => array:2 [ "nombre" => "Luis" "apellidos" => "Carreño" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Dosis efectiva mínimas de anti-TNF en artritis reumatoide: un estudio transversal" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1358 "Ancho" => 2328 "Tamanyo" => 220121 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Percentage of responders (DAS28 ≤3.2) and non-responders (DAS28 >3.2) in the different dosage regimens of anti-TNF treatments. ETN: etanercept; ADA; adalimumab; IFX: infliximab. Reduced (the time between doses was longer or the doses were lower than the standard ones). Standard (according to the approved prescribing information): ETN 25<span class="elsevierStyleHsp" style=""></span>mg twice a week or 50<span class="elsevierStyleHsp" style=""></span>mg weekly, ADA 40<span class="elsevierStyleHsp" style=""></span>mg every other week, and IFX 3<span class="elsevierStyleHsp" style=""></span>mg/kg every 8 weeks. Escalated (the time between doses was shorter or the doses were higher than the standard ones).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease with a fluctuant but progressive course, leading, without treatment, to cartilage damage, bone erosions, and joint destruction, the main causes of long-term disability.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Although the registered doses of anti-TNFs are at the top of the group dose response curve and under-treatment is not expected to be very frequent, the use of standard dosages in clinical practice may result in under or over treatment<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> once remission or low disease activity have been achieved, making it reasonable to attempt treating patients on an individualized schedule.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Clinical experience confirms the long-term efficacy of standard dosages for anti-TNF drugs, evaluation is still necessary to determine if reduced dosages could maintain clinically controlled patients. There are some reports addressing the issue of stopping, lowering, or increasing the dosages inpatients in remission,<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a> showing that up to 50% of patients relapse if the drug is stopped, and reintroduction of the therapy might not achieve previous results. However, tapering anti-TNF dosages seems to preserve the clinical efficacy in most patients.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Consequently, RA patients treated with anti-TNF who are in maintained remission<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> could benefit from treatment adjustment in order to find the lowest effective dose.</p><p id="par0020" class="elsevierStylePara elsevierViewall">The aim of the study was to assess the anti-TNF dosages in RA patients, evaluating whether modified patterns could control patients clinically under our daily clinical practice.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Patients and Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Study Design and Patient Population</span><p id="par0025" class="elsevierStylePara elsevierViewall">A cross-sectional, non-interventional study was conducted in the Hospital General Universitario Gregorio Marañón (HGUGM) in Madrid (Spain), from October 2010 to October 2011. During the study period, patients receiving anti-TNF for a minimum period of 12 months, and attending per routine follow-up the Biological Therapy Unit at the Rheumatology Department, were subsequently included. Requirements included being diagnosed with RA, according to the American College of Rheumatology's (ACR) 1987 revised criteria,<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> and treated with any of the following anti-TNF drugs: etanercept (ETN), adalimumab (ADA), or infliximab (IFX),administered either at standard or modified doses. <span class="elsevierStyleItalic">Standard therapy</span> was that in accordance with the approved prescribing information: ETN 25<span class="elsevierStyleHsp" style=""></span>mg twice a week or 50<span class="elsevierStyleHsp" style=""></span>mg weekly, ADA40<span class="elsevierStyleHsp" style=""></span>mg every other week, and IFX 3<span class="elsevierStyleHsp" style=""></span>mg/kg every 8 weeks. <span class="elsevierStyleItalic">Modified therapy</span> was either <span class="elsevierStyleItalic">escalated</span> (the time between doses was shorter or the doses were higher than the standard ones) or <span class="elsevierStyleItalic">reduced</span> (the time between doses was longer or the doses were lower than the standard ones). Dose tapering was adopted if the patient was in remission by DAS28 <2.6 or low activity <3.2 for those with very established and chronic disease for at least 1 year, based on a clinician and patient agreement, and not following any standardized protocol.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Study Variables</span><p id="par0030" class="elsevierStylePara elsevierViewall">The variables studied were the percentage of patients treated with each drug (IFX, ADA, and ETN), the prescribed dosages, the distribution of patients in clinical categories according to the Disease Activity Score (DAS28):<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> Remission (DAS28 <2.6); Low activity (DAS28: 2.6–3.2); Moderate activity (DAS28: 3.2–5.1); or High activity (DAS28 >5.1) in each treatment group, and the concomitant treatment with DMARDs: methotrexate (MTX), leflunomide (LF), sulfasalazine, andhydroxychloroquine.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Ethics</span><p id="par0035" class="elsevierStylePara elsevierViewall">The study was approved by the HGUGM Ethics Committee and all participants provided written informed consent.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Statistical Analyses</span><p id="par0040" class="elsevierStylePara elsevierViewall">Data was analyzed with the SPSS 17.0 statistical program. Continuous variables were described using mean and standard deviation (SD) or median and range. Categorical variables were described with frequencies and percentages. Statistical analyses including parametric and non-parametric tests in relation with variables distribution were performed comparing the 3 groups (ANOVA or Kruskal–Wallis test). Additional comparisons between IFX-ADA, IFX-ETN, and ETN-ADA groups were carried out using non-parametric or parametric tests (<span class="elsevierStyleItalic">U</span> Mann–Whitney, Chi square).</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Results</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Demographic and Clinical Data (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>)</span><p id="par0045" class="elsevierStylePara elsevierViewall">195 RA patients were included. Participants were predominantly women (79%) and the global mean age was 58.1 (±14.9) years. Patients were distributed into 3 groups, according to the anti-TNF drug used: 81 patients in the ETN group (41.5%), 56 in the ADA group (28.7%), and 58 in the IFX group (29.7%). Mean disease duration (years) was statistically different between groups (<span class="elsevierStyleItalic">P</span>=.01) although most patients (42.2%) had a mean disease duration between 10 and 20 years. In the 2–5 year range of duration, however, the percentage of patients in the ADA group was significantly higher when compared to ETN and IFX (<span class="elsevierStyleItalic">P</span>=.03). There were also significant differences between groups in terms of time from diagnosis to the administration of the first biological treatment. IFX was most commonly used as first-line biological treatment, whereas ETN was the option most commonly used as second-line.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Dosage Regimen and Clinical Disease Activity</span><p id="par0050" class="elsevierStylePara elsevierViewall">Most patients in ETN (72.8%) and ADA (69.6%) groups were treated with the standard dosages. In the ETN group there were no patients in escalated doses while most patients in IFX had an escalated regimen (69%). The percentage of patients with reduced doses were 27.1% and 25% for both the ETN and ADA groups respectively, with less than 4% in the IFX group.</p><p id="par0055" class="elsevierStylePara elsevierViewall">The distribution of patients in the ETN and ADA groups were similar, with most patients receiving the standard therapy, whereas in the IFX group there was a considerable proportion of patients with an escalated regimen. We found more than 60% of responders (DAS28 ≤3.2) in the ETN and ADA groups and less than 50% in the IFX one. <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> shows the distribution of responder and non-responder patients within the different treatment regimens (standard, escalated, and reduced) of the evaluated drugs. Both ETN (61.7%) and ADA (64.3%) groups had more responders than non-responders in any of the dosage regimens, even in the reduced one. On the other hand, the IFX group, despite having the higher number of patients in an escalated regimen, had globally less responders (48.3%), even at increased doses, where responders and non-responders were distributed at 50%. However, mean DAS28 value was similar for all anti-TNF (ETN: 2.8±1.5, ADA: 2.7±1.5,IFX: 3.3±1.5; <span class="elsevierStyleItalic">P</span>=.6). ETN patients, regardless of biologic line, were less likely to use concomitant DMARD than ADA or IFX patients. The drug more frequently used in association was methotrexate (MTX) followed by leflunomide (LEF).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Discussion</span><p id="par0060" class="elsevierStylePara elsevierViewall">Although clinical experience confirms the long-term efficacy of standard dosages for anti-TNF drugs, this study, based on our daily clinical experience, provides real-life data on the use of different dosage regimens. While the mean DAS28 value was similar between groups, we found more responders by DAS28 among patients in ETN and ADA groups when compared to IFX group, despite the higher percentage of patients with dose escalation in the latter group. IFX dose escalation in clinical practice has been reported elsewhere.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8–15</span></a> Nevertheless, in our cohort IFX was mainly used as a first line therapy, having a longer disease duration as well as a longer delay until biological treatment. The election of the drug and the different efficacies between anti-TNFs might be related to the patient's clinical and demographic characteristics, as well as the drugs available at the moment of starting biological treatment as well as the recent tendency to treat to target.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Nevertheless, when patients achieve clinical response, physicians can be constrained by the dosages specified in the summary of product characteristics (SPC). Real-life clinical practice supports the benefits of tailoring RA treatment, considering the severity of the condition, the effectiveness of each specific drug, and the risk of side effects. In our study over 40% of the patients were treated with either higher or lower dosages than those recommended in the approved prescribing information.</p><p id="par0070" class="elsevierStylePara elsevierViewall">Considering the cross-sectional design of the study, the interpretation of the results is limited since we cannot differentiate cause and effect from a simple association. In this sense, we have no information regarding patients in which dose reduction had been previously attempted without maintaining clinical response, and those who never tried dose titration. Also, we have identified some patients with very active disease or moderate disease activity on reduced dosage regimens. Even though this finding might be contradictory, those patients presented very established RA with chronic damage due to long-term disease duration, but no current clinical activity.</p><p id="par0075" class="elsevierStylePara elsevierViewall">DMARD use was lower for patients on ETN when compared to ADA and IFX. Better clinical efficacy of anti-TNF in combination with DMARD is broadly accepted,<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> however it is interesting to highlight the increased possibility of clinical control in our ETN group without concomitant DMARD, in accordance with other reports which give data of up to 50% of patients on ETN treatment inmonotherapy.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> However, non use of DMARDs have been broadly showed in patients after various biologics, and taking into account that ETN was the second line for most of the patients included <span class="elsevierStyleItalic">n</span> this study we cannot firmly conclude monotherapy as a good option only for ETN.</p><p id="par0080" class="elsevierStylePara elsevierViewall">Despite its limitations, this study has some strengths, since cross-sectional studies are useful at identifying associations and generating hypotheses.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> This study may be considered a good start point for controlled long-term trials that further investigate our findings. When a drug is effective at achieving disease control, it is important to consider the possibility of tapering doses whenever possible to reduce the cost and the possible long-term side effects.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Conclusions</span><p id="par0085" class="elsevierStylePara elsevierViewall">Regarding our results, it seems reasonable, when clinical response has been achieved, to try to reduce the standard dosage in order to establish the minimum effective dose, because tapered doses do not seem to lead to high disease activity in some patients.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflict of Interest</span><p id="par0090" class="elsevierStylePara elsevierViewall">The authors declare no conflict of interest.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Ethical Responsibilities</span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Protection of Human and Animal Subjects</span><p id="par0095" class="elsevierStylePara elsevierViewall">The authors declare that the procedures followed were in accordance with the regulations of the responsible Clinical Research Ethics Committee and in accordance with those of the World Medical Association and the Helsinki Declaration.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Confidentiality of Data</span><p id="par0100" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of their work centre on the publication of patient data and that all the patients included in the study have received sufficient information and have given their informed consent in writing to participate in that study.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Right to Privacy and Informed Consent</span><p id="par0105" class="elsevierStylePara elsevierViewall">The authors have obtained the informed consent of the patients and/or subjects mentioned in the article. The author for correspondence is in possession of this document.</p></span></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:2 [ "identificador" => "xres326257" "titulo" => array:5 [ 0 => "Abstract" 1 => "Aims" 2 => "Patients and methods" 3 => "Results" 4 => "Conclusions" ] ] 1 => array:2 [ "identificador" => "xpalclavsec307736" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres326256" "titulo" => array:5 [ 0 => "Resumen" 1 => "Objetivos" 2 => "Pacientes y métodos" 3 => "Resultados" 4 => "Conclusiones" ] ] 3 => array:2 [ "identificador" => "xpalclavsec307737" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Patients and Methods" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Study Design and Patient Population" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Study Variables" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Ethics" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Statistical Analyses" ] ] ] 6 => array:3 [ "identificador" => "sec0035" "titulo" => "Results" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Demographic and Clinical Data (Table 1)" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Dosage Regimen and Clinical Disease Activity" ] ] ] 7 => array:2 [ "identificador" => "sec0050" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0055" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "sec0060" "titulo" => "Conflict of Interest" ] 10 => array:3 [ "identificador" => "sec0065" "titulo" => "Ethical Responsibilities" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0070" "titulo" => "Protection of Human and Animal Subjects" ] 1 => array:2 [ "identificador" => "sec0075" "titulo" => "Confidentiality of Data" ] 2 => array:2 [ "identificador" => "sec0080" "titulo" => "Right to Privacy and Informed Consent" ] ] ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2013-07-18" "fechaAceptado" => "2013-07-24" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec307736" "palabras" => array:7 [ 0 => "Rheumatoid arthritis" 1 => "Anti-TNF" 2 => "Dosage titration" 3 => "DAS28" 4 => "Etanercept" 5 => "Adalimumab" 6 => "Infliximab" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec307737" "palabras" => array:7 [ 0 => "Artritis reumatoide" 1 => "Anti-TNF" 2 => "Ajuste de la dosis" 3 => "DAS28" 4 => "Etanercep" 5 => "Adalimumab" 6 => "Infliximab" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0010">Aims</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To evaluate the modified dosages of anti-TNF in controlling disease activity in rheumatoid arthritis (RA) measured by DAS28-ESR.</p> <span class="elsevierStyleSectionTitle" id="sect0015">Patients and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Cross-sectional study</span>: RA patients treated with etanercept (ETN), adalimumab (ADA) or infliximab (IFX), at standard or modified doses. <span class="elsevierStyleItalic">Main variables</span>: dosage, concomitant disease modifying drugs (DMARDs), DAS28-ESR.</p> <span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">195 RA patients included (79% women, mean age 58.1 years): ETN=81, ADA=56, IFX=58. Mean disease duration and time to first biological treatment was higher in IFX group (<span class="elsevierStyleItalic">P</span>=.01). Patients distribution by dosage: standard: ETN (72.8%), ADA (69.6%), IFX (27.6%); escalated: IFX (69%), ADA (5.4%), ETN (0%); reduced: ETN (27.1%), ADA (25%), IFX (3.4%). Concomitant DMARDs use was lower in ETN (58.2%) than ADA (66.07%) and IFX (79.31%). Higher proportion of responders (DAS28 ≤3.2) in ADA (65.3%) and ETN (61.7%) than IFX (48.3%).</p> <span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">RA clinical control can be preserved with modified anti-TNF dosages. Controlled prospective studies should be performed to define when therapy can be tailored and for which patients.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0035">Objetivos</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Avaluar dosis modificadas de anti-TNF en el control de actividad de la enfermedad en la artritis reumatoide (AR) medida por DAS28-VSG.</p> <span class="elsevierStyleSectionTitle" id="sect0040">Pacientes y métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Estudio transversal: pacientes con AR tratados con etanercept (ETN), adalimumab (ADA) o infliximab (IFX), en dosis estándar o modificada. Principales variables: dosis, enfermedad concomitante, fármacos modificadores (DMARDs), DAS28-VSG.</p> <span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">195 pacientes con AR fueron incluidos (79% mujeres, edad media 58,1 años): ETN = 81, ADA = 56, IFX = 58. La duración de la enfermedad y el tiempo medio hasta el primer tratamiento biológico fue mayor en el grupo con IFX (p = 0,01). Distribución de los pacientes por dosis estándar: ETN (72,8%), ADA (69,6%), IFX (27,6%); incremento: IFX (69%), ADA (5,4%), ETN (0%), reducción: ETN (27,1%), ADA (25%), IFX (3,4%). Uso concomitante DMARD fue menor en ETN (58,2%) que ADA (66,07%) e IFX (79,31%). La mayor proporción de respondedores (DAS28 ≤ 3,2) se vio en ADA (65,3%) y ETN (61,7%) que en IFX (48,3%).</p> <span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">El control clínico de la AR se puede preservar con dosis modificadas de anti-TNF. Estudios prospectivos controlados deben realizarse para definir cuando la terapia se puede adaptar y en que pacientes.</p>" ] ] "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1358 "Ancho" => 2328 "Tamanyo" => 220121 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Percentage of responders (DAS28 ≤3.2) and non-responders (DAS28 >3.2) in the different dosage regimens of anti-TNF treatments. ETN: etanercept; ADA; adalimumab; IFX: infliximab. Reduced (the time between doses was longer or the doses were lower than the standard ones). Standard (according to the approved prescribing information): ETN 25<span class="elsevierStyleHsp" style=""></span>mg twice a week or 50<span class="elsevierStyleHsp" style=""></span>mg weekly, ADA 40<span class="elsevierStyleHsp" style=""></span>mg every other week, and IFX 3<span class="elsevierStyleHsp" style=""></span>mg/kg every 8 weeks. Escalated (the time between doses was shorter or the doses were higher than the standard ones).</p>" ] ] 1 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">NS: no significant. ETN: etanercept; ADA: adalimumab; IFX: infliximab; DAS28: Disease Activity Score.</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">P</span> value: ANOVA test between the 3 groups.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">ETN (<span class="elsevierStyleItalic">n</span>: 81) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">ADA (<span class="elsevierStyleItalic">n</span>: 56) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">IFX (<span class="elsevierStyleItalic">n</span>: 58) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> value \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Demographics</span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Female;</span> n <span class="elsevierStyleItalic">(%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">64 (80) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38 (67.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">52 (89.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Age (years; mean±SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">53.2 (±15.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59.9 (±15.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">61.3 (±10.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">DAS28 (mean±SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.75 (±1.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.69 (±1.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.25 (±1.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Concomitant DMARD</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58.0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">66.1% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">79.3% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span>=.01 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Clinical disease duration (years; mean±SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.3 (±6.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10.5 (±6.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13.2 (±6.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span>=.01 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><2 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">2–5 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.8% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21.6% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10.9% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span>=.03 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">5–10 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31.4% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18.2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">10–20 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">41.9% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37.3% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">47.3% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">>20 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12.2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9.8% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">23.6% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Time from diagnosis to first anti-TNF treatment (years; mean±SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.7 (±5.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.9 (±5.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.5 (±4.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span>=.01 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><2 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17.6%<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.8%<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span>=.02<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">2–5 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25.7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31.4%<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">23.6% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span>=.02<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">5–10 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">27.0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31.4% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29.1% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">10–20 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18.9% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">23.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">40.0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">>20 years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.1% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ns \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">First-line biological option (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">63.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">70.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">87.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span>=.02 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Second-line biological option (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span>=.02 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab476177.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0005"><span class="elsevierStyleItalic">U</span>-Mann–Whitney comparison group per group.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Demographic and clinical characteristics of patients.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:19 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biologic agents in rheumatoid arthritis: an update for managed care professionals" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "S.K. Agarwal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.18553/jmcp.2011.17.s9-b.S14" "Revista" => array:7 [ "tituloSerie" => "J Manag Care Pharm" "fecha" => "2011" "volumen" => "17" "numero" => "9 Suppl. B" "paginaInicial" => "S14" "paginaFinal" => "S18" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22073935" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNFalpha" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.A. Den Broeder" 1 => "M.C. Creemers" 2 => "A.M. Van Gestel" 3 => "P.L. Van Riel" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2002" "volumen" => "41" "paginaInicial" => "638" "paginaFinal" => "642" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "K. Bendtzen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.30207" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2011" "volumen" => "63" "paginaInicial" => "867" "paginaFinal" => "870" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21452309" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differences in biologic dose-escalation non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.J. Moots" 1 => "B. Haraoui" 2 => "M. Matucci-Cerinic" 3 => "P.L. van Riel" 4 => "J. Kekow" 5 => "T. Schaeverbeke" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2011" "volumen" => "29" "paginaInicial" => "26" "paginaFinal" => "34" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21345289" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effects of low dose etanercept on disease control and radiographic progression in moderate to severe rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "B. Raffeiner" 1 => "C. Botsios" 2 => "P. Sfriso" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.27185" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2010" "volumen" => "62" "numero" => "10 Suppl." "paginaInicial" => "290" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20039398" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.S. Smolen" 1 => "R. Landewe" 2 => "F.C. Breedveld" 3 => "M. Buch" 4 => "G. Burmester" 5 => "M. Dougados" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.126532" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "paginaInicial" => "964" "paginaFinal" => "975" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20444750" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.C. Arnett" 1 => "S.M. Edworthy" 2 => "D.A. Bloch" 3 => "D.J. McShane" 4 => "J.F. Fries" 5 => "N.S. Cooper" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "1988" "volumen" => "31" "paginaInicial" => "315" "paginaFinal" => "324" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3358796" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Ogale" 1 => "E. Hitraya" 2 => "H.J. Henk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2474-12-204" "Revista" => array:5 [ "tituloSerie" => "BMC Musculoskelet Disord" "fecha" => "2011" "volumen" => "12" "paginaInicial" => "204" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21929807" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Finckh" 1 => "J.F. Simard" 2 => "C. Gabay" 3 => "P.A. Guerne" 4 => "S. Physicians" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2005.045062" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2006" "volumen" => "65" "paginaInicial" => "746" "paginaFinal" => "752" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16339288" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "R. Ariza-Ariza" 1 => "F. Navarro-Sarabia" 2 => "B. Hernandez-Cruz" 3 => "L. Rodriguez-Arboleya" 4 => "V. Navarro-Compan" 5 => "J. Toyos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2007" "volumen" => "46" "paginaInicial" => "529" "paginaFinal" => "532" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Double-blinded infliximab dose escalation in patients with rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.U. Rahman" 1 => "I. Strusberg" 2 => "P. Geusens" 3 => "A. Berman" 4 => "D. Yocum" 5 => "D. Baker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2006.065995" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2007" "volumen" => "66" "paginaInicial" => "1233" "paginaFinal" => "1238" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17392352" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Durez" 1 => "F. Van Den Bosch" 2 => "L. Corluy" 3 => "E.M. Veys" 4 => "L. De Clerck" 5 => "A. Peretz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2005" "volumen" => "44" "paginaInicial" => "465" "paginaFinal" => "468" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Pavelka" 1 => "K. Jarosova" 2 => "D. Suchy" 3 => "L. Senolt" 4 => "K. Chroust" 5 => "L. Dusek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2008.090860" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2009" "volumen" => "68" "paginaInicial" => "1285" "paginaFinal" => "1289" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19351624" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Van Der Maas" 1 => "W. Kievit" 2 => "B.J. Van Den Bemt" 3 => "F.H. Van Den Hoogen" 4 => "P.L. Van Riel" 5 => "A.A. Den Broeder" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2011-200945" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2012" "volumen" => "71" "paginaInicial" => "1849" "paginaFinal" => "1854" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22504561" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.J. Van Den Bemt" 1 => "A.A. Den Broeder" 2 => "G.F. Snijders" 3 => "Y.A. Hekster" 4 => "P.L. van Riel" 5 => "B. Benraad" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2007.083683" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2008" "volumen" => "67" "paginaInicial" => "1697" "paginaFinal" => "1701" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18245109" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metaanalysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L.G. Schipper" 1 => "L.T. Van Hulst" 2 => "R. Grol" 3 => "P.L. Van Riel" 4 => "M.E. Hulscher" 5 => "J. Fransen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2010" "volumen" => "49" "paginaInicial" => "2154" "paginaFinal" => "2164" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "British Society for Rheumatology Biologics Register" "etal" => false "autores" => array:6 [ 0 => "M.M. Soliman" 1 => "D.M. Ashcroft" 2 => "K.D. Watson" 3 => "M. Lunt" 4 => "D.P. Symmons" 5 => "K.L. Hyrich" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2010.139774" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2011" "volumen" => "70" "paginaInicial" => "583" "paginaFinal" => "589" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21330639" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Y. Yazici" 1 => "N. Shi" 2 => "A. John" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Bull NYU Hosp Jt Dis" "fecha" => "2008" "volumen" => "66" "paginaInicial" => "77" "paginaFinal" => "85" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18537774" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Observational research methods Research design II: cohort, cross sectional and case–control studies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "C.J. Mann" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Emerg Med J" "fecha" => "2003" "volumen" => "20" "paginaInicial" => "54" "paginaFinal" => "60" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12533370" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001000000002/v2_201403290120/S2173574314000379/v2_201403290120/en/main.assets" "Apartado" => array:4 [ "identificador" => "17338" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Original Article" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001000000002/v2_201403290120/S2173574314000379/v2_201403290120/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574314000379?idApp=UINPBA00004M" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 3 | 4 | 7 |
2024 October | 37 | 24 | 61 |
2024 September | 33 | 15 | 48 |
2024 August | 68 | 30 | 98 |
2024 July | 74 | 35 | 109 |
2024 June | 71 | 27 | 98 |
2024 May | 78 | 40 | 118 |
2024 April | 55 | 22 | 77 |
2024 March | 56 | 24 | 80 |
2024 February | 26 | 31 | 57 |
2024 January | 23 | 17 | 40 |
2023 December | 22 | 24 | 46 |
2023 November | 29 | 15 | 44 |
2023 October | 36 | 40 | 76 |
2023 September | 84 | 27 | 111 |
2023 August | 33 | 25 | 58 |
2023 July | 34 | 20 | 54 |
2023 June | 31 | 23 | 54 |
2023 May | 48 | 24 | 72 |
2023 April | 31 | 18 | 49 |
2023 March | 70 | 26 | 96 |
2023 February | 50 | 25 | 75 |
2023 January | 33 | 18 | 51 |
2022 December | 58 | 30 | 88 |
2022 November | 60 | 23 | 83 |
2022 October | 53 | 27 | 80 |
2022 September | 33 | 26 | 59 |
2022 August | 29 | 46 | 75 |
2022 July | 25 | 39 | 64 |
2022 June | 38 | 40 | 78 |
2022 May | 56 | 55 | 111 |
2022 April | 31 | 46 | 77 |
2022 March | 39 | 39 | 78 |
2022 February | 41 | 28 | 69 |
2022 January | 28 | 36 | 64 |
2021 December | 23 | 51 | 74 |
2021 November | 24 | 53 | 77 |
2021 October | 30 | 40 | 70 |
2021 September | 23 | 31 | 54 |
2021 August | 13 | 34 | 47 |
2021 July | 22 | 25 | 47 |
2021 June | 21 | 34 | 55 |
2021 May | 23 | 27 | 50 |
2021 April | 84 | 54 | 138 |
2021 March | 39 | 24 | 63 |
2021 February | 22 | 27 | 49 |
2021 January | 44 | 22 | 66 |
2020 December | 23 | 15 | 38 |
2020 November | 22 | 15 | 37 |
2020 October | 14 | 6 | 20 |
2020 September | 14 | 10 | 24 |
2020 August | 17 | 16 | 33 |
2020 July | 32 | 9 | 41 |
2020 June | 25 | 16 | 41 |
2020 May | 35 | 11 | 46 |
2020 April | 24 | 10 | 34 |
2020 March | 16 | 8 | 24 |
2020 February | 2 | 0 | 2 |
2018 May | 5 | 1 | 6 |
2018 April | 20 | 14 | 34 |
2018 March | 32 | 10 | 42 |
2018 February | 25 | 5 | 30 |
2018 January | 17 | 13 | 30 |
2017 December | 28 | 4 | 32 |
2017 November | 26 | 7 | 33 |
2017 October | 19 | 8 | 27 |
2017 September | 24 | 5 | 29 |
2017 August | 42 | 7 | 49 |
2017 July | 25 | 8 | 33 |
2017 June | 49 | 8 | 57 |
2017 May | 36 | 12 | 48 |
2017 April | 22 | 7 | 29 |
2017 March | 38 | 17 | 55 |
2017 February | 25 | 7 | 32 |
2017 January | 20 | 3 | 23 |
2016 December | 39 | 18 | 57 |
2016 November | 20 | 0 | 20 |
2016 October | 37 | 12 | 49 |
2016 September | 30 | 7 | 37 |
2016 August | 33 | 7 | 40 |
2016 July | 14 | 3 | 17 |
2016 April | 1 | 0 | 1 |
2015 December | 2 | 0 | 2 |
2015 September | 1 | 0 | 1 |
2015 August | 3 | 0 | 3 |
2015 July | 10 | 5 | 15 |
2015 June | 29 | 11 | 40 |
2015 May | 41 | 21 | 62 |
2015 April | 22 | 16 | 38 |
2015 March | 18 | 9 | 27 |
2015 February | 12 | 14 | 26 |
2015 January | 12 | 10 | 22 |
2014 December | 23 | 15 | 38 |
2014 November | 28 | 9 | 37 |
2014 October | 26 | 16 | 42 |
2014 September | 29 | 20 | 49 |
2014 August | 21 | 17 | 38 |
2014 July | 35 | 16 | 51 |
2014 June | 43 | 20 | 63 |
2014 May | 41 | 30 | 71 |
2014 April | 36 | 29 | 65 |
2014 March | 27 | 21 | 48 |